PMC Links for Books (Select 5225256) - PMC

Select item 82520521.

Pharmacokinetics and safety of ubrogepant when coadministered with calcitonin gene‒related peptide‐targeted monoclonal antibody migraine preventives in participants with migraine: A randomized phase 1b drug–drug interaction study

Abhijeet Jakate, Andrew M. Blumenfeld, Ramesh Boinpally, Matthew Butler, Lisa Borbridge, Janette Contreras‐De Lama, Danielle McGeeney, Antonia Periclou, Richard B. Lipton

Headache. 2021 Apr; 61(4): 642–652. Published online 2021 Apr 5. doi: 10.1111/head.14095

PMCID:: PMC8252052

Abstract Article PDF–291K

Select item 81400112.

Ubrogepant for the Acute Treatment of Migraine: Pooled Efficacy, Safety, and Tolerability From the ACHIEVE I and ACHIEVE II Phase 3 Randomized Trials

Susan Hutchinson, David W. Dodick, Christina Treppendahl, Nathan L. Bennett, Sung Yun Yu, Hua Guo, Joel M. Trugman

Neurol Ther. 2021 Jun; 10(1): 235–249. Published online 2021 Feb 20. doi: 10.1007/s40120-021-00234-7

PMCID:: PMC8140011

Abstract Article PDF–1.1M

Select item 72146473.

Ubrogepant Is Not Associated With Clinically Meaningful Elevations of Alanine Aminotransferase in Healthy Adult Males

Wendy Ankrom, Phung Bondiskey, Chi‐Chung Li, John Palcza, Wen Liu, Marissa F. Dockendorf, Catherine Matthews, Deborah Panebianco, Tom Reynders, John A. Wagner, Abhijeet Jakate, Sofie Mesens, Walter K. Kraft, Eugene E. Marcantonio

Clin Transl Sci. 2020 May; 13(3): 462–472. Published online 2020 Jan 3. doi: 10.1111/cts.12728

PMCID:: PMC7214647

Abstract Article PDF–305K

Select item 70626594.

Ubrogepant: First Approval

Lesley J. Scott

Drugs. 2020; 80(3): 323–328. Published online 2020 Feb 5. doi: 10.1007/s40265-020-01264-5

Correction in:: Drugs. 2020; 80(5): 523.

PMCID:: PMC7062659

Abstract Article PDF–777K

Select item 70042135.

Long‐Term Safety Evaluation of Ubrogepant for the Acute Treatment of Migraine: Phase 3, Randomized, 52‐Week Extension Trial

Jessica Ailani, Richard B. Lipton, Susan Hutchinson, Kerry Knievel, Kaifeng Lu, Matthew Butler, Sung Yun Yu, Michelle Finnegan, Lawrence Severt, Joel M. Trugman

Headache. 2020 Jan; 60(1): 141–152. Published online 2020 Jan 8. doi: 10.1111/head.13682

Correction in:: Headache. 2021 Jun; 61(6): 978–981.

PMCID:: PMC7004213

Abstract Article PDF–544K

Select item 69005706.

Safety and tolerability of ubrogepant following intermittent, high-frequency dosing: Randomized, placebo-controlled trial in healthy adults

Peter J Goadsby, Stewart J Tepper, Paul B Watkins, Girma Ayele, Rosa Miceli, Matthew Butler, Lawrence Severt, Michelle Finnegan, Armin Szegedi, Joel M Trugman, Abhijeet Jakate

Cephalalgia. 2019 Dec; 39(14): 1753–1761. Published online 2019 Sep 19. doi: 10.1177/0333102419869918

PMCID:: PMC6900570

Abstract Article PDF–418K

Select item 68653237.

Effect of Ubrogepant vs Placebo on Pain and the Most Bothersome Associated Symptom in the Acute Treatment of Migraine: The ACHIEVE II Randomized Clinical Trial

Richard B. Lipton, David W. Dodick, Jessica Ailani, Kaifeng Lu, Michelle Finnegan, Armin Szegedi, Joel M. Trugman

JAMA. 2019 Nov 19; 322(19): 1887–1898. Published online 2019 Nov 19. doi: 10.1001/jama.2019.16711

Correction in:: JAMA. 2020 Apr 7; 323(13): 1318.

PMCID:: PMC6865323

Abstract Article

PMC

Result Filters

Article attributes

Text availability

Publication date

Custom date range

Research Funder

Additional filters

Display Settings:

Send to:

Links from Books

Items: 7

Display Settings:

Send to:

Supplemental Content

Find related data

Recent activity